A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Add Yahoo as a preferred source to see more of our stories on Google. Unlike typical glaucoma treatments that slow progression, this approach aims to rejuvenate the retinal ganglion cells that die ...

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the close of a ...

Boston-based Life Biosciences is testing whether reprogramming human cells can slow or even reverse the effects of aging. Unsplash Life Biosciences, a Boston-based biotechnology company founded in ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare combination of premature physical aging and progressive neurological decline caused ...

For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

Scientists at the Salk Institute for Biological Studies and Sanford Burnham Prebys explore genetic factors in separate papers ...